A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913

Chinnaiyan, Prakash; Won, Minhee; Y. Wen, Patrick; M. Rojiani, Amyn; Werner‐Wasik, Maria; A. Shih, Helen; S. Ashby, Lynn; Michael Yu, Hsiang-Hsuan; W. Stieber, Volker; Malone, Shawn; B. Fiveash, John; Mohile, Nimish; S. Ahluwalia, Manmeet; M Wendland, Merideth; J. Stella, Philip; Y. Kee, Andrew; P. Mehta, Minesh

doi:10.1093/neuonc/nox209

Public

A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913

Published in Neuro-Oncology • Oct 30, 2017

Authors:

Prakash Chinnaiyan

Minhee Won

Patrick Y. Wen

Abstract

Background: This phase II study was designed to determine the efficacy of the mammalian target of rapamycin (mTOR) inhibitor everolimus administered daily with conventional radiation therapy and chemotherapy in patients with newly diagnosed glioblastoma. Methods: Patients were randomized to radiatio...

Subject

Everolimus

Temozolomide

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!